Exactly, and having steered a very long trial to successful conclusion and manufacturing as skillfully as they have so far, given the common challenges otherwise with cell therapy manufacturing, especially when we note the complexity of a highly personalized product like DCVax-L, a deferred bonus is entirely reasonable.
There are some who want to make employees and management as miserable as possible and try not only to drive shareholders away, but executives, from these nascent companies. Anything to disrupt, undermine and delay success seems to be on the table with a certain set of traders and social media chaos agents.
Bullish
Market Data 
Markets 
AI
